---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-214504"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:37:03.142335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaccinex announces publication of Phase 2 SIGNAL HD study in Nature Medicine showing pepinemab slows cognitive decline

## Summary
- Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.
- Pepinemab significantly improved cognition in early manifest HD patients (HD-CAB Index p=0.007).
- Pepinemab reduced caudate atrophy (p=0.017) and brain metabolic decline in FDG-PET.
- Treatment was well-tolerated with 5% treatment-emergent adverse events vs 9% placebo.
- Phase 1b/2a study of pepinemab in Alzheimer's disease initiated (NCT04381468).

## SEC filing metadata
- accession: 0001193125-22-214504
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/0001193125-22-214504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/d320536d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-214504
- JSON: https://secwatch.observer/filing/0001193125-22-214504.json
- Plain text: https://secwatch.observer/filing/0001193125-22-214504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.